|
US6228362B1
(en)
|
1992-08-21 |
2001-05-08 |
Immunomedics, Inc. |
Boron neutron capture therapy using pre-targeting methods
|
|
US5846741A
(en)
*
|
1992-08-21 |
1998-12-08 |
Immunomedics, Inc. |
Boron neutron capture therapy using pre-targeting methods
|
|
US7011812B1
(en)
*
|
1996-05-03 |
2006-03-14 |
Immunomedics, Inc. |
Targeted combination immunotherapy of cancer and infectious diseases
|
|
AU717020B2
(en)
*
|
1996-05-03 |
2000-03-16 |
Immunomedics Inc. |
Targeted combination immunotherapy of cancer
|
|
US6331289B1
(en)
|
1996-10-28 |
2001-12-18 |
Nycomed Imaging As |
Targeted diagnostic/therapeutic agents having more than one different vectors
|
|
US6261537B1
(en)
|
1996-10-28 |
2001-07-17 |
Nycomed Imaging As |
Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
|
|
BR9712683A
(pt)
|
1996-10-28 |
1999-10-19 |
Nyomed Imaging A S |
Agente de diagnóstico e/ou terapeuticamente ativo alvejável, formulação combinada, processo para preparação e uso do mesmo, formulação combinada, e processos para gerar imagens intensificadas de um corpo animal humano ou não-humano e para investigação in vitro de alvejamento por um agente.
|
|
US7405320B2
(en)
|
1998-06-22 |
2008-07-29 |
Immunomedics, Inc. |
Therapeutic and diagnostic conjugates for use with multispecific antibodies
|
|
US7833528B2
(en)
|
1998-06-22 |
2010-11-16 |
Immunomedics, Inc. |
Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
|
|
US7387772B1
(en)
|
1999-06-22 |
2008-06-17 |
Immunimedics, Inc. |
Chimeric, human and humanized anti-CSAP monoclonal antibodies
|
|
US7138103B2
(en)
*
|
1998-06-22 |
2006-11-21 |
Immunomedics, Inc. |
Use of bi-specific antibodies for pre-targeting diagnosis and therapy
|
|
US6962702B2
(en)
|
1998-06-22 |
2005-11-08 |
Immunomedics Inc. |
Production and use of novel peptide-based agents for use with bi-specific antibodies
|
|
US6361774B1
(en)
|
1999-09-17 |
2002-03-26 |
Immunomedics, Inc. |
Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
|
|
EP1113819B1
(de)
|
1998-09-18 |
2011-02-23 |
Immunomedics, Inc. |
Antikörper verwiesene enzymprodrugtherapie mit glukuronidase
|
|
US8383081B2
(en)
*
|
1999-05-10 |
2013-02-26 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods of use
|
|
US7829064B2
(en)
*
|
1999-05-10 |
2010-11-09 |
Immunomedics, Inc. |
Anti-CD74 immunoconjugates and methods
|
|
US8119101B2
(en)
*
|
1999-05-10 |
2012-02-21 |
The Ohio State University |
Anti-CD74 immunoconjugates and methods of use
|
|
US6596849B1
(en)
*
|
1999-05-28 |
2003-07-22 |
Academia Sinica |
Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules
|
|
NO314537B1
(no)
*
|
1999-12-06 |
2003-04-07 |
Anticancer Therapeutic Inv Sa |
Reseptorbindende konjugater
|
|
WO2001097855A2
(en)
*
|
2000-06-20 |
2001-12-27 |
Immunomedics, Inc. |
Targeted combination immunotherapy of cancer and infectious diseases
|
|
EP1389209B1
(de)
*
|
2001-04-24 |
2009-04-08 |
Purdue Research Foundation |
Folat-mimetika und deren folatrezeptorbindende konjugate
|
|
GB0112844D0
(en)
*
|
2001-05-25 |
2001-07-18 |
Psimei Pharmaceuticals Plc |
Neutron capture therapy
|
|
US20040043030A1
(en)
*
|
2001-07-31 |
2004-03-04 |
Immunomedics, Inc. |
Polymeric delivery systems
|
|
CN1604966A
(zh)
*
|
2001-10-15 |
2005-04-06 |
免疫医疗公司 |
直接靶定的结合蛋白
|
|
US20050069549A1
(en)
|
2002-01-14 |
2005-03-31 |
William Herman |
Targeted ligands
|
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
|
CA2476166C
(en)
*
|
2002-02-14 |
2011-11-15 |
Immunomedics, Inc. |
Anti-cd20 antibodies and fusion proteins thereof and methods of use
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
KR101017732B1
(ko)
|
2002-03-01 |
2011-02-28 |
이뮤노메딕스, 인코오포레이티드 |
내재화 항-cd74 항체 및 그 이용방법
|
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
|
CA2478047C
(en)
|
2002-03-01 |
2014-01-21 |
Immunomedics, Inc. |
Rs7 antibodies
|
|
EP1575507A2
(de)
*
|
2002-04-02 |
2005-09-21 |
Scantibodies Laboratory, Inc. |
Verfahren und vorrichtungen zur behandlung von schweren peripheren bakteriellen infektionen
|
|
KR20040106547A
(ko)
*
|
2002-05-15 |
2004-12-17 |
엔도사이트, 인코포레이티드 |
비타민-마이토마이신 공액체
|
|
ES2524767T3
(es)
|
2002-06-14 |
2014-12-12 |
Immunomedics, Inc. |
Anticuerpo monoclonal humanizado HPAM4
|
|
KR101115797B1
(ko)
|
2002-08-01 |
2012-07-27 |
이뮤노메딕스, 인코오포레이티드 |
알파 태아 단백질 Immu31 항체 및 융합단백질, 및이들의 이용 방법
|
|
US7541440B2
(en)
|
2002-09-30 |
2009-06-02 |
Immunomedics, Inc. |
Chimeric, human and humanized anti-granulocyte antibodies and methods of use
|
|
KR20050065587A
(ko)
|
2002-10-08 |
2005-06-29 |
이뮤노메딕스, 인코오포레이티드 |
항체 치료법
|
|
EP1558284B1
(de)
*
|
2002-10-08 |
2013-09-11 |
Immunomedics, Inc. |
Kombinationstherapie mit nakten klasse iii anti-cea monoklonalen antikörpern und therapeutischen wirkstoffen
|
|
US7651689B2
(en)
*
|
2002-11-15 |
2010-01-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
Methods of applying ionization radiation for therapy of infections
|
|
US8420086B2
(en)
|
2002-12-13 |
2013-04-16 |
Immunomedics, Inc. |
Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
|
|
US7534427B2
(en)
*
|
2002-12-31 |
2009-05-19 |
Immunomedics, Inc. |
Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
|
|
US7601332B2
(en)
|
2003-01-27 |
2009-10-13 |
Endocyte, Inc. |
Vitamin receptor binding drug delivery conjugates
|
|
US7402385B2
(en)
|
2003-02-11 |
2008-07-22 |
Albert Einstein College Of Medicine Of Yeshiva University |
Radiolabeled antibodies for treatment of tumors
|
|
US8709998B2
(en)
*
|
2003-04-22 |
2014-04-29 |
Ipsen Pharma S.A.S. |
Peptide vectors
|
|
JP4937751B2
(ja)
*
|
2003-06-13 |
2012-05-23 |
イミューノメディクス、インコーポレイテッド |
D−アミノ酸ペプチド
|
|
EP1660519B1
(de)
*
|
2003-07-29 |
2014-05-14 |
Immunomedics, Inc. |
Konjugate von 2-[18F]Fluor-2-desoxy-D-glucose und einem Peptid-Molekül
|
|
JP4733635B2
(ja)
|
2003-07-31 |
2011-07-27 |
イミューノメディクス、インコーポレイテッド |
抗cd19抗体
|
|
US20050059101A1
(en)
*
|
2003-09-10 |
2005-03-17 |
Gordon Ringold |
Bivalent targeting of cell surfaces
|
|
US9481878B2
(en)
|
2004-02-13 |
2016-11-01 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US8883160B2
(en)
*
|
2004-02-13 |
2014-11-11 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US20110171126A1
(en)
*
|
2010-01-11 |
2011-07-14 |
Center For Molecular Medicine And Immunology |
Enhanced Cytotoxicity of Anti-CD74 and Anti-HLA-DR Antibodies with Interferon-Gamma
|
|
US8551480B2
(en)
*
|
2004-02-13 |
2013-10-08 |
Immunomedics, Inc. |
Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
|
|
US9550838B2
(en)
|
2004-02-13 |
2017-01-24 |
Ibc Pharmaceuticals, Inc. |
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
JP2008505853A
(ja)
|
2004-04-13 |
2008-02-28 |
クインテセンス バイオサイエンシーズ インコーポレーティッド |
細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
|
|
EP1771205B1
(de)
|
2004-06-18 |
2016-10-26 |
Ambrx, Inc. |
Neuartige antigen-bindende polypeptide und ihre verwendungen
|
|
CN101098854B
(zh)
|
2004-07-23 |
2012-12-05 |
恩多塞特公司 |
二价连接体及其轭合物
|
|
ES2381557T3
(es)
|
2004-08-03 |
2012-05-29 |
Innate Pharma |
Métodos terapéuticos y de diagnóstico y composiciones para determinar 4IG-B7-H3 y su receptor homólogo en las células NK
|
|
US20060057062A1
(en)
*
|
2004-09-10 |
2006-03-16 |
Trotter Dinko G |
Compositions and methods useful in pretargeted imaging
|
|
RU2481356C2
(ru)
|
2004-12-28 |
2013-05-10 |
Иннейт Фарма |
Моноклональные антитела против nkg2a
|
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
|
CN101171034B
(zh)
|
2005-03-03 |
2014-06-18 |
免疫医疗公司 |
人源化l243抗体
|
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
CN101175757B
(zh)
*
|
2005-03-16 |
2012-11-14 |
恩多塞特公司 |
蝶酸及其缀合物的合成和纯化
|
|
EP2551282A3
(de)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antikörper gegen CD38 zur Behandling von multiplem Myelom
|
|
US8475794B2
(en)
|
2005-04-06 |
2013-07-02 |
Ibc Pharmaceuticals, Inc. |
Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
|
|
US8349332B2
(en)
|
2005-04-06 |
2013-01-08 |
Ibc Pharmaceuticals, Inc. |
Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
|
|
JP2009504783A
(ja)
*
|
2005-08-19 |
2009-02-05 |
エンドサイト,インコーポレイテッド |
ビンカアルカロイド、類似体および誘導体のリガンド結合体
|
|
RU2470668C2
(ru)
*
|
2005-08-19 |
2012-12-27 |
Эндосайт, Инк. |
Конъюгаты лиганда с несколькими лекарственными средствами
|
|
EP1934260B1
(de)
|
2005-10-14 |
2017-05-17 |
Innate Pharma |
Zusammensetzungen und methoden zur behandlung proliferierender krankheiten
|
|
EP2674440B1
(de)
|
2005-12-16 |
2019-07-03 |
IBC Pharmaceuticals, Inc. |
Polyvalente bioaktive anordnungen auf immunglobulinbasis
|
|
US8840882B2
(en)
*
|
2006-06-23 |
2014-09-23 |
Quintessence Biosciences, Inc. |
Modified ribonucleases
|
|
DK2038306T3
(en)
|
2006-06-30 |
2015-03-09 |
Novo Nordisk As |
ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
|
|
WO2008010991A2
(en)
|
2006-07-17 |
2008-01-24 |
Quintessence Biosciences, Inc. |
Methods and compositions for the treatment of cancer
|
|
WO2009077483A1
(en)
|
2007-12-14 |
2009-06-25 |
Novo Nordisk A/S |
Antibodies against human nkg2d and uses thereof
|
|
CN101626787A
(zh)
*
|
2007-01-19 |
2010-01-13 |
马林克罗特公司 |
诊断的和治疗的环氧合酶-2结合配体
|
|
US20100104626A1
(en)
*
|
2007-02-16 |
2010-04-29 |
Endocyte, Inc. |
Methods and compositions for treating and diagnosing kidney disease
|
|
CN104127878A
(zh)
*
|
2007-03-14 |
2014-11-05 |
恩多塞特公司 |
结合配体连接的微管溶素递药缀合物
|
|
US9877965B2
(en)
|
2007-06-25 |
2018-01-30 |
Endocyte, Inc. |
Vitamin receptor drug delivery conjugates for treating inflammation
|
|
BRPI0812970A2
(pt)
*
|
2007-06-25 |
2019-09-24 |
Endocyte Inc |
conjugados contendo espaçadores hidrofílicos
|
|
CA2699394C
(en)
|
2007-09-17 |
2020-03-24 |
The Regents Of The University Of California |
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
|
|
CA2702043A1
(en)
*
|
2007-10-08 |
2009-04-16 |
Quintessence Biosciences, Inc. |
Compositions and methods for ribonuclease-based therapies
|
|
EP2209374B1
(de)
|
2007-10-25 |
2014-12-03 |
Endocyte, Inc. |
Tubulysine und verfahren zu ihrer herstellung
|
|
MX2010007935A
(es)
|
2008-01-24 |
2010-08-23 |
Novo Nordisk As |
Anticuerpo monoclonal humanizado anti-nkg2a humano.
|
|
CN102159243B
(zh)
*
|
2008-07-21 |
2015-08-19 |
免疫医疗公司 |
用于改良的治疗特征的抗体的结构变体
|
|
BRPI0920743A2
(pt)
|
2008-10-01 |
2016-09-20 |
Quintessence Biosciences Inc |
ribonucleases terapeuticas
|
|
PL3912643T3
(pl)
|
2009-02-13 |
2023-01-23 |
Immunomedics Inc. |
Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
|
|
WO2011034660A1
(en)
|
2009-09-16 |
2011-03-24 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
IN2012DN03354A
(de)
|
2009-12-02 |
2015-10-23 |
Immunomedics Inc |
|
|
US20140170068A1
(en)
|
2011-03-11 |
2014-06-19 |
Board Of Regents Of The University Of Nebraska |
Biomarker for coronary artery disease
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
US9192664B2
(en)
|
2011-12-05 |
2015-11-24 |
Immunomedics, Inc. |
Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
|
|
US9757458B2
(en)
|
2011-12-05 |
2017-09-12 |
Immunomedics, Inc. |
Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
|
|
WO2013126797A1
(en)
|
2012-02-24 |
2013-08-29 |
Purdue Research Foundation |
Cholecystokinin b receptor targeting for imaging and therapy
|
|
US20140080175A1
(en)
|
2012-03-29 |
2014-03-20 |
Endocyte, Inc. |
Processes for preparing tubulysin derivatives and conjugates thereof
|
|
EP3553089A1
(de)
|
2012-05-10 |
2019-10-16 |
Bioatla, LLC |
Multispezifische monoklonale antikörper
|
|
AU2013302696B9
(en)
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
EA201590622A1
(ru)
|
2012-10-16 |
2015-10-30 |
Эндосайт, Инк. |
Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
|
|
CN107753954A
(zh)
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
|
US20240148873A1
(en)
|
2012-12-13 |
2024-05-09 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
|
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
|
US12310958B2
(en)
|
2012-12-13 |
2025-05-27 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
|
WO2015012904A2
(en)
|
2012-12-13 |
2015-01-29 |
Immunomedics, Inc. |
Antibody-sn-38 immunoconjugates with a cl2a linker
|
|
WO2014125041A1
(en)
|
2013-02-14 |
2014-08-21 |
Innate Pharma |
Treatment of peripheral t cell lymphoma
|
|
DK3896088T3
(da)
|
2013-02-20 |
2025-09-29 |
Innate Pharma |
Behandling af perifert t-cellelymfom
|
|
US9561291B2
(en)
*
|
2013-03-15 |
2017-02-07 |
Imre Kovesdi |
Methods of targeting T-cells to tumors
|
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
|
PT3057585T
(pt)
|
2013-10-15 |
2020-10-21 |
Seagen Inc |
Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
|
|
ES2978993T3
(es)
|
2014-02-21 |
2024-09-23 |
Ibc Pharmaceuticals Inc |
Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
|
|
CA2935748A1
(en)
|
2014-02-25 |
2015-09-03 |
Immunomedics, Inc. |
Humanized rfb4 anti-cd22 antibody
|
|
JP6787789B2
(ja)
*
|
2014-04-04 |
2020-11-18 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
詰め替え可能な薬物送達デバイスおよびその使用方法
|
|
WO2015189477A1
(en)
|
2014-06-13 |
2015-12-17 |
Tenboron Oy |
Conjugates comprising an anti-egfr1 antibody
|
|
US9580495B2
(en)
|
2014-06-24 |
2017-02-28 |
Immunomedics, Inc. |
Anti-histone therapy for vascular necrosis in severe glomerulonephritis
|
|
WO2016030488A1
(en)
|
2014-08-27 |
2016-03-03 |
Innate Pharma |
Treatment of celiac disease
|
|
PL3204018T3
(pl)
|
2014-10-07 |
2022-01-03 |
Immunomedics, Inc. |
Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek
|
|
WO2016086036A2
(en)
|
2014-11-25 |
2016-06-02 |
Bristol-Myers Squibb Company |
Methods and compositions for 18f-radiolabeling of biologics
|
|
EP3286224A4
(de)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
|
|
PT3313443T
(pt)
|
2015-06-25 |
2023-08-30 |
Immunomedics Inc |
Combinação de anticorpos anti-hla-dr ou anti-trop-2 com inibidores de microtúbulos, inibidores de parp, inibidores de bruton quinase ou inibidores de fosfoinositídeo 3-quinase melhora significativamente o resultado terapêutico no cancro
|
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
|
EP3316871A4
(de)
|
2015-06-30 |
2019-02-20 |
The Trustees of Columbia University in the City of New York |
Talkgebundene zusammensetzung und verwendungen davon
|
|
PL3316885T3
(pl)
|
2015-07-01 |
2021-12-06 |
Immunomedics, Inc. |
Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a
|
|
EP3383920B1
(de)
|
2015-11-30 |
2024-01-10 |
The Regents of the University of California |
Freisetzung von tumorspezifischer nutzlast und immunaktivierung mit einem menschlichen antikörper gegen hochspezifisches tumorzellenoberflächenantigen
|
|
US11229708B2
(en)
|
2015-12-04 |
2022-01-25 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
US11793880B2
(en)
|
2015-12-04 |
2023-10-24 |
Seagen Inc. |
Conjugates of quaternized tubulysin compounds
|
|
CN108601841A
(zh)
|
2016-02-10 |
2018-09-28 |
免疫医疗公司 |
Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
|
|
EP3433278A4
(de)
|
2016-03-25 |
2019-11-06 |
Seattle Genetics, Inc. |
Verfahren zur herstellung von pegylierten wirkstoff-linkern und zwischenprodukten davon
|
|
US10634680B2
(en)
|
2016-04-26 |
2020-04-28 |
University Of Utah Research Foundation |
Target-binding activated split reporter systems for analyte detection and related components and methods
|
|
RU2725292C2
(ru)
|
2016-04-27 |
2020-06-30 |
Иммьюномедикс, Инк. |
Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
|
|
WO2017201111A1
(en)
|
2016-05-19 |
2017-11-23 |
Bristol-Myers Squibb Company |
Pet-imaging immunomodulators
|
|
WO2017210335A1
(en)
|
2016-06-01 |
2017-12-07 |
Bristol-Myers Squibb Company |
Imaging methods using 18f-radiolabeled biologics
|
|
EP3538551A4
(de)
|
2016-11-10 |
2020-11-11 |
Fortis Therapeutics, Inc. |
Cd46-specifische effektorzellen und verwendungen davon
|
|
JP7527787B2
(ja)
|
2017-03-24 |
2024-08-05 |
シージェン インコーポレイテッド |
グルクロニド薬物-リンカーの調製のためのプロセスおよびその中間体
|
|
RU2758234C2
(ru)
|
2017-03-27 |
2021-10-26 |
Иммьюномедикс, Инк. |
ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51
|
|
CA3044082A1
(en)
|
2017-04-03 |
2018-10-11 |
Immunomedics, Inc. |
Subcutaneous administration of antibody-drug conjugates for cancer therapy
|
|
CN112513081A
(zh)
|
2018-06-14 |
2021-03-16 |
生物蛋白有限公司 |
多重特异性抗体构建体
|
|
CN115397835A
(zh)
*
|
2020-04-24 |
2022-11-25 |
国立大学法人东京大学 |
倍癌霉素衍生物及其应用
|
|
JP2023534765A
(ja)
|
2020-08-07 |
2023-08-10 |
フォーティス セラピューティクス,インク. |
免疫複合体を標的とするcd46およびその使用方法
|
|
CN116744981A
(zh)
*
|
2021-01-13 |
2023-09-12 |
豪夫迈·罗氏有限公司 |
组合疗法
|
|
EP4342497A1
(de)
|
2021-05-10 |
2024-03-27 |
Kawasaki Institute of Industrial Promotion |
Antikörper mit reduzierter bindungsaffinität für antigen
|
|
WO2026092759A1
(en)
|
2024-11-04 |
2026-05-07 |
Modex Therapeutics, Inc. |
Multispecific antibodies and methods of use thereof
|